Acneiform eruption following molecular targeted chemotherapy

Internal Medicine Journal

Volumn 41, Issue 4, 2011, Pages 361-362

  Vaccaro, M ^a   Barbuzza, O ^b   Pollicino, A ^c   Guarneri, C ^a  

^a Institute of Dermatology   (Italy)

^b School and Division of Allergology and Clinical Immunology   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOYL PEROXIDE; CETUXIMAB; CLINDAMYCIN; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ACNE; ADULT; BEDTIME DOSAGE; CANCER STAGING; CASE REPORT; COLON ADENOCARCINOMA; DOSE RESPONSE; DRUG TOLERANCE; FOLLICULITIS; HISTOPATHOLOGY; HUMAN; INFLAMMATORY INFILTRATE; MALE; METASTASIS; MOLECULARLY TARGETED THERAPY; NOTE; PAPULAR RASH; PRIORITY JOURNAL; PRURITUS; PUSTULE; SEBORRHEA; SKIN BIOPSY; SKIN BURNING SENSATION; SKIN TOXICITY;

ACNEIFORM ERUPTIONS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; GENE TARGETING; HUMANS; MALE; MIDDLE AGED;

EID: 79955041515     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2011.02429.x     Document Type: Note

References (4)

1. Morse L, Calarese P. EGFR-targeted therapy and related skin toxicity. Semin Oncol Nurs 2006; 22: 152-62.
2. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55: 657-70.
3. Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 2007; 56: 317-26.
4. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007; 12: 610-21.